Stay updated with breaking news from Optimizing Patient Outcomes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, emphasize the importance of shared decision-making, comprehensive data, and well-informed multidisciplinary team collaboration in delivering high-quality, patient-centered care, while highlighting the benefits of tailored adjuvant therapies.
Medical professionals discuss proactive symptom management for adverse events like diarrhea, hair thinning, cytopenia, and neutropenia, offering guidance on dose reduction and treatment holds to optimize patient outcomes while minimizing adverse effects.
Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, provide an in-depth analysis of the randomized phase III monarchE trial, which focused on Abemaciclib in high-risk early-stage HR+, HER2- breast cancer, offering insights into recurrence rates, progression-free survival, and distant disease-free survival outcomes for patients.
Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, examine the NCCN guidelines compared to real-world evidence, particularly in the treatment of menopausal, pre-menopausal, and high-risk early-stage HR+/HER2- patients.
Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, discuss the biological and pathological risk factors influencing breast cancer development, treatment, and risk stratification.